HIV

The TZA test is faster, more cost-effective, and less labor-intensive than the current test for finding dormant HIV cells.

Gilead plans to file for approval of novel HIV drug in the United States and Europe this year.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses trends in specialty drug cost management.

HIV-positive individuals are twice as likely to die of smoking than the disease.

Patients with HIV can now expect to live into old age, and therefore need links to the community health network.

Many community pharmacists wonder what they can and should do for their patients who have HIV.

Isentress has been used as a component of treatment regimens for patients diagnosed with HIV-1 for almost a decade.

Isentress HD is a once daily treatment for HIV-1 that helps patients achieve viral suppression.

Cost of once daily version of Isentress will match price for twice daily HIV drug.

Novel strategy prolongs immune system defense against HIV.

Individuals with HIV are at 1.5-2 times the risk of cardiovascular disease and a disproportionate risk of death.

Epoetin alfa biosimilar has indications in cancer, HIV, and chronic kidney disease, among other conditions.

This is the first recommendation for a proposed erythropoiesis-stimulating agent biosimilar.

Scientists project combining prevention programs could avert up to 40,000 HIV infections over 20 years among injection drug users.

Collaboration is part of a citywide plan to ensure patients with HIV receive care and to reduce the number of new HIV transmissions.

A laboratory test that could potentially identify gonorrhea infections that may be more treatable with antibiotics.

Researchers from UCLA have developed a laboratory test that could potentially identify gonorrhea infections that may be more treatable with antibiotics.

HIV infection may affect cognition in young patients.

Continuing ART post-delivery shows benefits in women with early stage HIV,

The continuum of HIV care enables countries to monitor the success of their HIV response, from diagnosis to viral suppression.

Non-EU and EEA countries trail behind in reaching viral suppression target by 2020.

In a study published in Nature Medicine, investigators found that when a virus enters the bloodstream it activates the first responder immune cells, CX3CR1highLY6Clow monocytes.

Virus-driven immune activation blocks connections between nerve cells in the brain.

The criminalization of drug use could be detrimental to HIV patient health and does not decrease use, study suggests.